Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NKVYN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RG-7882
|
|||||
| Synonyms |
D-4064A; DMUC-4064A; RG7882; RG 7882; DMUC 4064A; DMUC4064A
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.; Roche Holding AG
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 4 Indication(s)
Fallopian tube cancer [ICD11:2C74]
Terminated in phase 1
Ovarian cancer [ICD11:2C73]
Terminated in phase 1
Pancreatic cancer [ICD11:2C10]
Terminated in phase 1
Peritoneal cancer [ICD11:2C51]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
MMUC3333A
|
Antibody Info | ||||
| Antigen Name |
Mucin-16 (MUC16)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Protease cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.